Physician profile
Raphaelle D Vallera
NPI 1790777365
$5,254.16
in general payments reported to CMS, 2019-2025
45 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $244 · 2021: $12.71 · 2022: $195 · 2023: $1,176 · 2024: $1,008 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,296.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $572.02 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $411.94 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Amgen INC. | $317.65 | 2019-2025 | Tepezza, Evenity |
| Amneal Pharmaceuticals LLC | $304.44 | 2019-2025 | Unithroid |
| Radius Health, INC. | $285.68 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $279.54 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $270.52 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $214.95 | 2022-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $207.06 | 2019-2025 | Ozempic |
| Dexcom, INC. | $185.22 | 2019-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $162.64 | 2019-2023 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.30 | 2019-2025 | Jardiance |
| Pfizer INC. | $148.37 | 2019-2025 | |
| Antares Pharma, INC. | $142.21 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $142.04 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $132.80 | 2019 | |
| Abbvie INC. | $123.14 | 2019-2025 | Synthroid |
| Ibsa Pharma INC. | $103.41 | 2019-2025 | Tirosint, Licart, Flector |
| Astrazeneca Pharmaceuticals Lp | $95.79 | 2019-2020 | |
| Shire North American Group INC | $84.67 | 2019 | |
| Mannkind Corporation | $73.18 | 2019-2025 | Afrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.16 | 2019 | |
| Beta Bionics, INC. | $64.48 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $63.16 | 2024-2025 | |
| Averitas Pharma INC. | $55.55 | 2024 | Qutenza |
| Kyowa Kirin, INC. | $52.24 | 2023-2025 | Crysvita |
| Medtronic, INC. | $47.71 | 2022-2025 | Minimed 780g |
| Insulet Corporation | $46.86 | 2019-2023 | Omnipod |
| Embecta Corp. | $44.11 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Regeneron Healthcare Solutions, INC. | $41.48 | 2019 | |
| Sequel Med Tech, LLC | $39.19 | 2025 | Twiist |
| Ipsen Biopharmaceuticals, INC | $34.06 | 2019 | |
| Eisai INC. | $29.45 | 2019 | |
| Halozyme INC | $28.87 | 2023 | |
| Companion Medical, INC. | $28.77 | 2019 | |
| Ascendis Pharma Endocrinology INC | $25.24 | 2025 | Yorvipath |
| Rhythm Pharmaceuticals, INC. | $24.50 | 2025 | Imcivree |
| Amarin Pharma, INC. | $24.46 | 2019 | |
| Cequr Corporation | $21.95 | 2022 | |
| Alvogen INC | $19.71 | 2023 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $18.19 | 2023 | |
| Gilead Sciences, INC. | $18.15 | 2019 | |
| Medtronic Minimed, INC. | $16.67 | 2019 | |
| Tolmar, INC. | $16.09 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphaelle Vallera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.